Toxic encephalopathy

Summary

Toxic encephalopathy (MONDO:0005527) is a disease (an umbrella term covering 5 Mondo subtypes) and 86 clinical trials. Top therapeutic interventions include procarbazine, amifostine, and amitriptyline. A subtype of nervous system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 5 Mondo subtypes
• Clinical trials: 86

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	toxic encephalopathy
Mondo ID	MONDO:0005527
EFO	EFO:0005595
MeSH	D020258
DOID	DOID:3602
ICD-10-CM	G92
NCIT	C27961
SNOMED CT	28394000
GARD	0007199
Is cancer (heuristic)	no

Also known as: neurotoxicity · neurotoxicity syndrome · neurotoxicity syndromes

Disease family

This is a subtype of nervous system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › toxic encephalopathy

Related subtypes (71): congenital nervous system disorder, central nervous system disorder, autoimmune disorder of the nervous system, cranial nerve neuropathy, peripheral nervous system disorder, neuronitis, diplegia of upper limb, retinal disorder, developmental disability, restless legs syndrome, movement disorder, Barre-Lieou syndrome, Gerstmann syndrome, drug-induced akathisia, drug-induced dyskinesia, stiff-person syndrome, Worster-Drought syndrome, corneal-cerebellar syndrome, pachygyria-intellectual disability-epilepsy syndrome, porencephaly-cerebellar hypoplasia-internal malformations syndrome, symmetrical thalamic calcifications, neonatal brainstem dysfunction, primary orthostatic hypotension, rippling muscle disease with myasthenia gravis, periodic paralysis, qualitative or quantitative protein defects in neuromuscular diseases, specific learning disability, cerebellar hypoplasia-tapetoretinal degeneration syndrome, locked-in syndrome, dopa-responsive dystonia, idiopathic recurrent stupor, chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids, spontaneous periodic hypothermia, Sydenham chorea, duplication of the pituitary gland, Balint syndrome, paraneoplastic neurologic syndrome, persistent idiopathic facial pain, serotonin syndrome, hypothalamic adipsic hypernatraemia syndrome, exercise-induced malignant hyperthermia, perineural cyst, neuromuscular disease, neuromyelitis optica, AL amyloidosis, AA amyloidosis, neuroleptic malignant syndrome, infectious disorder of the nervous system, central nervous system malformation, synaptopathy, nervous system neoplasm, sensory ganglionopathy, radiculitis, wet beriberi, perceptual disorders, prepubertal anorexia nervosa, neurocutaneous syndrome, neurovascular disorder, Wallerian degeneration, nervous system injury, neurosarcoidosis, neuroendocrine disorder, tubulinopathy, atactic disorder, hereditary neurological disease, meningitis-retention syndrome, KIF1A related neurological disorder, neurological pain disorder, neurodevelopmental disorder, post 5-alpha-reductase inhibitors treatment syndrome, post-selective serotonin reuptake inhibitor sexual dysfunction

Subtypes (5): hepatic encephalopathy, carbon monoxide-induced delayed encephalopathy, manganese poisoning, Minamata disease, chronic bilirubin encephalopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 86.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	36
PHASE3	23
PHASE2	16
PHASE4	6
EARLY_PHASE1	2
PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05089604	PHASE4	RECRUITING	Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations
NCT00754767	PHASE4	TERMINATED	L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer
NCT02864030	PHASE4	COMPLETED	PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
NCT03461445	PHASE4	COMPLETED	Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients
NCT03823768	PHASE4	COMPLETED	Envarsus Neurotoxicity Burden in Liver Transplant Patients
NCT05094154	PHASE4	COMPLETED	Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
NCT00978458	PHASE3	ACTIVE_NOT_RECRUITING	Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
NCT03089905	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Compare the Long-term Outcomes After Two Different Anaesthetics
NCT00027963	PHASE3	COMPLETED	Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy
NCT00046891	PHASE3	COMPLETED	EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
NCT00058071	PHASE3	COMPLETED	Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer
NCT00068445	PHASE3	COMPLETED	Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
NCT00112996	PHASE3	COMPLETED	Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer
NCT00301080	PHASE3	TERMINATED	D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain
NCT00316914	PHASE3	COMPLETED	Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
NCT00363129	PHASE3	COMPLETED	Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer
NCT00369564	PHASE3	COMPLETED	Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
NCT00471445	PHASE3	COMPLETED	Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
NCT00489411	PHASE3	COMPLETED	Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
NCT00516503	PHASE3	COMPLETED	Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
NCT00566852	PHASE3	COMPLETED	Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
NCT00775645	PHASE3	COMPLETED	S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo
NCT00807768	PHASE3	UNKNOWN	Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
NCT01099449	PHASE3	COMPLETED	Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
NCT01279681	PHASE3	TERMINATED	Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
NCT01372774	PHASE3	COMPLETED	Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
NCT01492920	PHASE3	WITHDRAWN	Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
NCT02311907	PHASE3	COMPLETED	Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
NCT02486198	PHASE3	COMPLETED	Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer
NCT00003072	PHASE2	COMPLETED	Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer
NCT00003624	PHASE2	TERMINATED	Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
NCT00069927	PHASE2	TERMINATED	Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression
NCT00078845	PHASE2	COMPLETED	Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
NCT00365768	PHASE2	COMPLETED	Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
NCT00666484	PHASE2	COMPLETED	Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma
NCT00727831	PHASE1/PHASE2	COMPLETED	Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
NCT00792142	PHASE2	COMPLETED	Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
NCT00884767	PHASE2	UNKNOWN	Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
NCT00952848	PHASE2	COMPLETED	Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy
NCT01381718	PHASE2	COMPLETED	Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PROCARBAZINE	4	8
AMIFOSTINE	4	4
AMITRIPTYLINE	4	3
DEXTROMETHORPHAN	4	3
PENICILLIN G	4	3
CALCIUM GLUCONATE	4	2
CISPLATIN	4	2
GLUCARPIDASE	4	2
MAGNESIUM SULFATE	4	2
OXALIPLATIN	4	2
ANAKINRA	4	1
AXICABTAGENE CILOLEUCEL	4	1
BACLOFEN	4	1
CEFTOLOZANE	4	1
CYCLOSERINE	4	1
DULOXETINE	4	1
ERIBULIN MESYLATE	4	1
GINKGO	4	1
GLUTAMINE	4	1
LAMOTRIGINE	4	1
LEVOCARNITINE	4	1
LITHIUM CARBONATE	4	1
MEMANTINE	4	1
MODAFINIL	4	1
TEMOZOLOMIDE	4	1
VITAMIN E	4	1
2,2’-DITHIODIETHANESULFONIC ACID	3	2
ACETYLCARNITINE	3	2
CEPHALOSPORIN	3	1
DEFIBROTIDE	3	1